You are here: Home » 2025 » August » Archives for 27th

Countdown For A Cure Awards $350,000 Grant to Minovia Therapeutics to Advance Groundbreaking Mitochondrial Biomarker Research

ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) — Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine, today announced a $350,000 grant to Minovia Therapeutics Ltd., a clinical–stage company pioneering mitochondrial transplantation technologies. The funding will support Minovia’s research proposal to develop novel mitochondrial blood–based biomarkers that quantify mitochondrial content, quality, and function, with the goal of establishing a standardized “MitoScore.”

In addition to developing mitochondrial augmentation and transplantation (MAT)–based therapies, Minovia has set dual goals: advancing biomarkers to measure mitochondrial health and using these biomarkers to compare mitochondrial scores in healthy individuals and patients with mitochondrial disease. By doing so, Minovia aims to provide tools for earlier diagnosis, better disease tracking, and more effective evaluation of therapies.

Mitochondrial dysfunction is a hallmark not only of rare genetic diseases but also of chronic and age–related conditions. Despite its central role in human health, impacting the brain, heart, muscles, metabolism, and immunity, there are no approved therapies or functional diagnostic tests for mitochondrial dysfunction. When mitochondria become damaged or stop working properly, cells fail to produce enough energy, triggering a ripple effect that undermines nearly every system in the body. Causes can range from genetics and aging to environmental toxins, infections, poor diet, chronic stress, and medications. Because dysfunction often hides behind seemingly unrelated symptoms, it is frequently misdiagnosed or missed entirely, earning its reputation as the “hidden root cause” of disease.

“We shouldn’t just be fixing disease; we should be funding the future of health and healing. Supporting Minovia’s biomarker work is a crucial step in advancing mitochondrial medicine to the forefront of healthcare, not only for patients living with rare mitochondrial diseases, but also for the millions worldwide facing conditions linked to mitochondrial dysfunction. As one of the most overlooked drivers of health and disease, mitochondrial dysfunction plays a central role in everything from neurodegeneration and chronic fatigue to aging and metabolic disorders. By addressing this profound unmet need, we have an opportunity to transform how medicine prevents, diagnoses, and treats disease at its root,” said Mitzi Solomon, Founder & President of Countdown For A Cure Foundation.

Dr. Noa Sher, Chief Scientific Officer of Minovia, commented: “We are grateful to Countdown For A Cure Foundation, whose support will be instrumental in advancing the development of blood–based functional mitochondrial biomarkers. These tools will enable the identification of patients most likely to benefit from our MAT technology, as well as support patient follow–up after treatment. Given how critical mitochondria are to human health, we envision a future where mitochondrial biomarker assessments are part of routine checkups for individuals of all ages.”

About Minovia Therapeutics

Founded in 2011, Minovia Therapeutics, chaired by John Cox, is a clinical–stage biotechnology company developing treatments to replace dead or defective mitochondria with healthy mitochondria, helping people with mitochondrial diseases and fighting aging. Its lead therapy, MNV–201, is already in clinical testing for Pearson Syndrome and Myelodysplastic Syndrome.

The company is recognized globally for leading the first clinical trials in mitochondrial transplantation and continues to pioneer innovative therapies and biomarker development to bring energy–based healing to patients worldwide. Beyond rare mitochondrial diseases, Minovia is expanding its applications to broader areas where mitochondrial dysfunction plays a central role, including neurodegeneration, chronic fatigue, aging, and metabolic disorders.

Based in Haifa, Israel, Minovia operates a GMP facility for mitochondrial drug substance and drug product manufacturing to support its clinical trials, and it is planning expansion into the United States.

For more information, visit www.minoviatx.com.

About Countdown For A Cure

Countdown For A Cure (CFAC) is a foundation dedicated to accelerating mitochondrial medicine. Founded in 2024 by Mitzi and Jeff Solomon, who experienced mitochondrial dysfunction and its effects on their family firsthand, CFAC partners with leading research institutions and patient advocacy groups to fund bold, high–impact science and provide critical support to families. As a smart charity, CFAC invests in next–generation solutions for preventing, diagnosing, treating, and ultimately curing diseases rooted in cellular energy dysfunction, while also advancing healthy aging and extending longevity.

CFAC envisions a future where mitochondrial medicine revolutionizes healthcare by extending healthspan, transforming lives, and bringing energy–based healing to the forefront of medicine. Mitochondrial dysfunction affects nearly every area of medicine, including the brain, heart, muscles, and metabolism, yet it remains one of the most overlooked drivers of disease.

That is why CFAC is committed to advancing science, bridging clinical care, raising awareness of mitochondrial health, and uniting a global community determined to make a tangible difference in the lives of those affected by conditions and diseases linked to mitochondrial dysfunction.

For more information, visit www.countdownforacure.org.

Contacts:

Countdown For A Cure
Mitzi Solomon, Founder and President
[email protected] | +1 (917) 715–2381

Jeff Solomon, Founder
[email protected] | +1 (404) 272–0959

Vivian Martin, Communications Associate
[email protected] | +1 (404) 754–3337


GLOBENEWSWIRE (Distribution ID 9519437)

WOOF Deadline: WOOF Investors with Losses in Excess of $100K Have Opportunity to Lead Petco Health and Wellness Company, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”), of the important August 29, 2025 lead plaintiff deadline.

So what: If you purchased Petco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Petco class action, go to https://rosenlegal.com/submit–form/?case_id=41009 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 29, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Petco’s pandemic–related tailwinds were unsustainable, as was its business model of selling primarily premium and/or high–grade pet food; (2) accordingly, the strength of Petco’s differentiated product strategy was overstated; (3) defendants downplayed the true scope and severity of the foregoing issues, the magnitude of changes needed to rectify those issues, and the likely negative impacts of their mitigation strategy on Petco’s comparable sales metric; (4) accordingly, defendants overstated Petco’s ability to deliver sustainable, profitable growth; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Petco class action, go to https://rosenlegal.com/submit–form/?case_id=41009 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9519129)

IRBT DEADLINE: ROSEN, A TOP-RANKED FIRM, Encourages iRobot Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – IRBT

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline.

SO WHAT: If you purchased iRobot securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the iRobot class action, go to https://rosenlegal.com/submit–form/?case_id=23275 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) iRobot overstated the extent to which the Restructuring Plan would help iRobot maintain stability after the termination of the Amazon Acquisition; (2) as a result, it was unlikely that iRobot would be able to profitably operate as a standalone company; (3) accordingly, there was substantial doubt about iRobot’s ability to continue as a going concern; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the iRobot class action, go to https://rosenlegal.com/submit–form/?case_id=23275 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9519185)

IRBT DEADLINE: ROSEN, A TOP-RANKED FIRM, Encourages iRobot Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action – IRBT

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline.

SO WHAT: If you purchased iRobot securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the iRobot class action, go to https://rosenlegal.com/submit–form/?case_id=23275 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) iRobot overstated the extent to which the Restructuring Plan would help iRobot maintain stability after the termination of the Amazon Acquisition; (2) as a result, it was unlikely that iRobot would be able to profitably operate as a standalone company; (3) accordingly, there was substantial doubt about iRobot’s ability to continue as a going concern; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the iRobot class action, go to https://rosenlegal.com/submit–form/?case_id=23275 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9519185)

BHVN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Biohaven Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BHVN

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), of the important September 12, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Biohaven securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Biohaven class action, go to https://rosenlegal.com/submit–form/?case_id=41650 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) troriluzole’s regulatory prospects as a treatment for spinocerebellar ataxia (“SCA”), and/or the sufficiency of data that Biohaven submitted in support of troriluzole’s regulatory approval for this indication, were overstated; (2) BHV–7000’s efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven’s business and financial condition; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Biohaven class action, go to https://rosenlegal.com/submit–form/?case_id=41650 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
[email protected]
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9519140)

CNC DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Centene Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important September 8 Deadline in Securities Class Action – CNC

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”), of the important September 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Centene securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Centene class action, go to https://rosenlegal.com/submit–form/?case_id=41552 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period provided investors with material information concerning Centene’s expected revenue guidance and adjusted diluted earnings per share (“EPS”) for the 2025 fiscal year. Defendants’ statements included, among other things, confidence in Centene’s enrollment and morbidity rates, as well as strong retention rates in Centene’s Medicare business. Defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene’s enrollment and morbidity rates. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Centene class action, go to https://rosenlegal.com/submit–form/?case_id=41552 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9519138)

WAMCO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Western Asset Management Company, LLC Mutual Fund Investors with Losses in Excess of $100K to Secure Counsel Before Important September 5 Deadline in Securities Class Action

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the “Western Asset US Core Bond Fund” mutual fund classes – Class I (ticker: “WATFX”), Class A (ticker: “WABAX”), Class C (ticker: “WABCX”), Class FI (ticker: “WAPIX”), Class IS (ticker: “WACSX”), and Class R (ticker: “WABRX”) – and the “Western Asset Core Plus Bond Fund” mutual fund classes – Class A (ticker: “WAPAX”), Class C (ticker: “WAPCX”), Class C1 (ticker: “LWCPX”), Class FI (ticker: “WACIX”), Class R (ticker: “WAPRX”), Class I (ticker: “WACPX”), Class IS (ticker: “WAPSX”) between January 1, 2021 and October 31, 2023, inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline.

SO WHAT: If you purchased WAMCO mutual funds during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the WAMCO class action, go to https://rosenlegal.com/submit–form/?case_id=31956 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants failed to warn investors that: (1) defendants favored certain WAMCO strategies, like Macro Opps, over other WAMCO strategies, like Core and Core Plus; (2) defendants disfavored certain WAMCO strategies, like Core and Core Plus; (3) any “compliance policies and procedures” that WAMCO maintained “to result in fair allocations of investment opportunities to clients” were either insufficient to ensure that Leech and his WAMCO Team fairly allocated trades among the strategies they managed or were expressly disregarded by defendants in order to allow the favoring of certain WAMCO strategies at the expense of other WAMCO strategies; (3) any “oversight mechanisms” that WAMCO maintained were either insufficient to monitor Leech and his WAMCO Team or were expressly disregarded by defendants in order to allow the favoring of certain WAMCO strategies at the expense of other WAMCO strategies. As a result, defendants’ actions operated as a fraud or deceit on the Class, artificially reducing the price of the “Western Asset US Core strategy” mutual fund classes during the Class Period, damaging Class members.

To join the WAMCO class action, go to https://rosenlegal.com/submit–form/?case_id=31956 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9519173)

CAPR DEADLINE: ROSEN, A TRUSTED INVESTOR RIGHTS FIRM, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CAPR

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Capricor class action, go to https://rosenlegal.com/submit–form/?case_id=42281 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants provided investors with material information concerning deramiocel, Capricor’s lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Further, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four–year safety and efficacy data from its Phase 2 HOPE–2 trial study of deramiocel. The lawsuit alleges this caused shareholders to purchase Capricor’s securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Capricor class action, go to https://rosenlegal.com/submit–form/?case_id=42281 or call Phillip Kim, Esq. at 866–767–3653 or email [email protected] for more information.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        [email protected]
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9519107)

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

  • Funding supports next–generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug–repurposing
  • Initial clients reporting commercial success, revolutionizing indication selection of lead programs
  • Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals

WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or the “Company”), a technology–driven company that integrates mathematical algorithm–led approaches with complementary cybernetics to optimize decision–making processes, is pleased to announce the successful closing of its $10 million Seed funding round, led by third–party investor, Corvus Capital.

Sarborg has achieved significant commercial and technical milestones from its development plan, since its inception in 2024. The issuance of $10 million of Convertible Promissory Notes highlights investor confidence in Sarborg’s novel approach and rapid development delivering commercial milestones.

Looking forward, the proceeds of the fundraising will enable Sarborg to scale its AI–driven drug development and deploy agents across expanded client portfolios, while diversifying its client and equity partnership base. Sarborg will continue to deepen its intellectual property portfolio and look to broaden its agentic approach to fields beyond pharmaceuticals.

Successful Launch and Strong Commercial Validation

Sarborg has quickly capitalized on early revenue–generation, with the successful execution of an initial services agreement with a NASDAQ–listed Pharmaceutical Company, validating its core technologies and a repurposing strategy based on their lead–program drug–signature model.

Sarborg has delivered personalized dashboards to clients, a critical tool designed to provide key personnel with real–time access to data related to deliverables, research and development oversight, and drug discovery. Furthermore, Sarborg has built a proprietary portfolio of over 800 disease signatures, each uniquely mapped using its proprietary data–driven approach and now focusing on an agentic–approach to repurposing without human intervention.

Proceeds from the fundraising will be strategically deployed to:

  • Advance Sarborg’s proprietary AI agents focused on drug repurposing, target identification, and clinical trial optimization.
  • Develop novel pharmaceutical IP, transforming underused molecules into novel IP through solid–form engineering and formulation expertise.
  • Grow Sarborg’s internal pipeline of pharmaceutical assets for monetization via outlicensing or royalty–based deal structures.
  • Expand the client base and revenue–generating service business to fund ongoing innovation and reduce dilution in future rounds.

Following the demand for its seed financing, the Company expects to shortly launch a follow–on Series A financing round to enable Sarborg to scale globally and solidify its position as a category leader in AI–driven agentic innovation, combining new equity, tokenized securities and crypto–based blockchain technologies across multiple verticals.

About Sarborg Limited

Sarborg is a technology–driven company that integrates proprietary AI–agents and mathematical algorithm–based approaches with complementary cybernetics and extensive neural networks, to optimize decision–making processes. Its current principal vertical is focused on evaluating drug repurposing matching unique drug and disease signatures for pharmaceutical companies, leveraging machine learning and algorithmic strategies to enhance asset portfolio management and improve the probability of success in clinical trials. The Company is planning its expansion into further analytic areas beyond pharmaceuticals.

The company is composed of a seasoned and highly experienced team in cybernetics and signature development, drug development, medical affairs and commercialization, regulatory affairs, IP and manufacturing. Since its inception in 2024, Sarborg has applied its suite of AI agents, cybernetic algorithms, and machine learning capabilities across various sectors, enabling a highly efficient decision–making process throughout its portfolio.

Investors & Media:
[email protected]
www.sarborg.com


GLOBENEWSWIRE (Distribution ID 9519004)

SOUEAST Drives into Fashion: Exclusive Auto Sponsor of Dubai Fashion Week 2025-2026

DUBAI, United Arab Emirates, Aug. 27, 2025 (GLOBE NEWSWIRE) — SOUEAST has officially announced a significant partnership as the exclusive automotive partner of Dubai Fashion Week 2025–2026, with its debut appearance at the Spring/Summer Show this September. This marks Dubai Fashion Week’s first–ever collaboration with a Chinese automotive brand, positioning SOUEAST as the second automotive partner in the event’s history, following Maserati.

(Official Automobile Partner of Dubai Fashion Week: SOUEAST）

Ranked among the world’s top five fashion weeks, Dubai Fashion Week is co–founded by Dubai Design District (d3) and the Arab Fashion Council (AFC). As an internationally important event, Dubai Fashion Week emphasizes fashion, eco–consciousness and sustainability, committed to showcasing Dubai's creative energy and commercial appeal, while earning a place on the global fashion stage.

SOUEAST, a representative urban lifestyle automotive brand, has been committed to its 'EASE YOUR LIFE' philosophy since its 2024 renewal. Aligning seamlessly with Dubai Fashion Week, the brand consistently embeds eco–consciousness and sustainability at the core of its development. The brand focuses on addressing the diverse mobility needs of global urban youth. This year, SOUEAST has launched new models across the UAE, Saudi Arabia, Qatar and Kuwait. By integrating its campaigns with iconic, fashionable landmarks in each region, the brand has rapidly captured the attention of local youth. This partnership will further spread the 'EASE YOUR LIFE' ethos to a wider global audience. Moving forward, SOUEAST will embark on strategic collaborations with renowned designers, seamlessly fusing cutting–edge automotive engineering with high fashion aesthetics to create truly extraordinary mobility experiences. This strategic partnership will leverage the influential platform of Dubai Fashion Week to establish new trends in urban mobility.

The collaboration serves as Dubai Fashion Week’s first annual partnership with a Chinese automotive brand. SOUEAST’s logo is now on the event’s official website as a sponsor. As the official automotive partner for both the Spring–Summer and Fall–Winter events, SOUEAST will not only debut at the show in September 2025, but also engage deeply in international fashion events throughout the year, solidifying its premium and global brand identity.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c637adb7–b050–4585–8e73–eb81df9c80f5


GLOBENEWSWIRE (Distribution ID 9519049)